NO20023780D0 - Dipeptid nitril katepsin K inhibitorer - Google Patents

Dipeptid nitril katepsin K inhibitorer

Info

Publication number
NO20023780D0
NO20023780D0 NO20023780A NO20023780A NO20023780D0 NO 20023780 D0 NO20023780 D0 NO 20023780D0 NO 20023780 A NO20023780 A NO 20023780A NO 20023780 A NO20023780 A NO 20023780A NO 20023780 D0 NO20023780 D0 NO 20023780D0
Authority
NO
Norway
Prior art keywords
inhibitors
dipeptide nitrile
nitrile cathepsin
cathepsin
dipeptide
Prior art date
Application number
NO20023780A
Other languages
English (en)
Other versions
NO20023780L (no
Inventor
Martin Missbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20023780L publication Critical patent/NO20023780L/no
Publication of NO20023780D0 publication Critical patent/NO20023780D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20023780A 2000-02-10 2002-08-09 Dipeptid nitril katepsin K inhibitorer NO20023780D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0003111.2A GB0003111D0 (en) 2000-02-10 2000-02-10 Organic compounds
PCT/EP2001/001359 WO2001058886A1 (en) 2000-02-10 2001-02-08 Dipeptide nitrile cathepsin k inhibitors

Publications (2)

Publication Number Publication Date
NO20023780L NO20023780L (no) 2002-08-09
NO20023780D0 true NO20023780D0 (no) 2002-08-09

Family

ID=9885359

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023780A NO20023780D0 (no) 2000-02-10 2002-08-09 Dipeptid nitril katepsin K inhibitorer

Country Status (31)

Country Link
US (4) US6642239B2 (no)
EP (1) EP1254124B1 (no)
JP (1) JP3942895B2 (no)
KR (1) KR100544553B1 (no)
CN (2) CN1636980A (no)
AR (1) AR029466A1 (no)
AT (1) ATE402930T1 (no)
AU (1) AU764334B2 (no)
BR (1) BR0108118A (no)
CA (1) CA2396158C (no)
CO (1) CO5261578A1 (no)
CZ (1) CZ20022721A3 (no)
DE (1) DE60135087D1 (no)
ES (1) ES2310177T3 (no)
GB (1) GB0003111D0 (no)
HK (1) HK1050197A1 (no)
HU (1) HUP0300148A3 (no)
IL (1) IL150406A0 (no)
MX (1) MXPA02007768A (no)
MY (1) MY122826A (no)
NO (1) NO20023780D0 (no)
NZ (1) NZ519940A (no)
PE (1) PE20020220A1 (no)
PL (1) PL200119B1 (no)
PT (1) PT1254124E (no)
RU (2) RU2265601C2 (no)
SK (1) SK11462002A3 (no)
TR (1) TR200201752T2 (no)
TW (1) TWI258473B (no)
WO (1) WO2001058886A1 (no)
ZA (1) ZA200206218B (no)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
SK12882001A3 (sk) 1999-03-15 2002-04-04 Axys Pharmaceuticals, Inc. Zlúčeniny a prípravky ako proteinázové inhibítory
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US7064123B1 (en) 2000-12-22 2006-06-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
IL160819A0 (en) 2001-09-14 2004-08-31 Aventis Pharma Inc Novel compounds and compositions as cathepsin inhibitors
US6977256B2 (en) 2001-11-14 2005-12-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin S inhibitors
SI1482924T1 (sl) * 2002-03-05 2008-12-31 Merck Frosst Canada Ltd Katepsin cistein proteazni inhibitorji
WO2004052921A1 (en) * 2002-12-05 2004-06-24 Axys Pharmaceuticals, Inc. Cyanomethyl derivatives as cysteine protease inhibitors
CA2530068A1 (en) * 2003-06-30 2005-01-06 Merck Frosst Canada Ltd. Cyanoalklamino derivatives useful as cathepsin cysteine protease inhibitors
JP2006528151A (ja) * 2003-07-21 2006-12-14 ノバルティス アクチエンゲゼルシャフト 骨転移、腫瘍増殖および腫瘍誘発骨量減少の処置におけるカテプシンｋ阻害剤およびビスホスホネートの組み合わせ
WO2005049028A1 (en) * 2003-11-19 2005-06-02 Novartis Ag Use of cathepsin k inhibitors in severe bone loss diseases
ATE461200T1 (de) 2004-01-08 2010-04-15 Medivir Ab Inhibitoren von cysteinprotease
CN101065137A (zh) * 2004-09-16 2007-10-31 加利福尼亚大学董事会 用于改善动脉粥样硬化和其它病变的g型多肽和其它剂
RU2414236C2 (ru) 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
EP1841419A4 (en) * 2005-01-19 2009-02-25 Merck Frosst Canada Ltd INHIBITORS OF CATHEPSIN K AND OBESITY
WO2006076797A1 (en) * 2005-01-19 2006-07-27 Merck Frosst Canada Ltd. Cathepsin k inhibitors and atherosclerosis
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
GB0517637D0 (en) * 2005-08-30 2005-10-05 Novartis Ag Organic compounds
JP4047365B2 (ja) 2006-01-11 2008-02-13 生化学工業株式会社 シクロアルカンカルボキサミド誘導体及びその製造方法
US8829209B2 (en) 2006-01-11 2014-09-09 Seikagaku Corporation Cycloalkylcarbonylamino acid ester derivative and process for producing the same
JP3975226B2 (ja) * 2006-01-11 2007-09-12 生化学工業株式会社 シクロアルキルカルボニルアミノ酸誘導体及びその製造方法
AU2007253796A1 (en) * 2006-05-22 2007-11-29 Velcura Therapeutics, Inc. Use of Cathepsin K antagonists in bone production
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614046D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
CN101970007A (zh) 2007-06-08 2011-02-09 日本化学医药株式会社 脑动脉瘤的治疗或预防药
BRPI0702541A2 (pt) 2007-06-21 2009-02-10 Petroleo Brasileiro Sa processo de craqueamento catalÍtico para produÇço de diesel a partir de sementes de oleaginosas
US7893067B2 (en) 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
JPWO2009054454A1 (ja) 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
WO2009076490A1 (en) * 2007-12-12 2009-06-18 Velcura Therapeutics, Inc. Use of cathepsin l antagonists in the treatment of bone disease
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases
EP2262783A2 (en) * 2008-02-21 2010-12-22 Sanofi-Aventis Covalently binding imaging probes
GB0817425D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
US20100298507A1 (en) 2009-05-19 2010-11-25 Menschig Klaus R Polyisobutylene Production Process With Improved Efficiencies And/Or For Forming Products Having Improved Characteristics And Polyisobutylene Products Produced Thereby
MX2013013281A (es) 2011-05-16 2013-12-06 Bayer Ip Gmbh Uso de la inhibicion de la catepsina k para el tratamiento y/o profilaxis de hipertension pulmonar y/o insuficiencia cardiaca.
EP2537532A1 (en) 2011-06-22 2012-12-26 J. Stefan Institute Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use
US9593138B2 (en) 2012-10-05 2017-03-14 Wayne State University Nitrile-containing enzyme inhibitors and ruthenium complexes thereof
WO2014199645A1 (ja) 2013-06-14 2014-12-18 生化学工業株式会社 α－オキソアシルアミノカプロラクタム体
EP3009444B1 (en) 2013-06-14 2017-12-20 Seikagaku Corporation Alpha-oxoacyl amino-caprolactam derivative

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3467691A (en) 1964-04-22 1969-09-16 Tsutomu Irikura N-(n-acylaminoacyl)-aminoacetonitriles
US5206249A (en) 1991-03-27 1993-04-27 Du Pont Merck Pharmaceutical Company Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
EP0547699A1 (en) 1991-12-19 1993-06-23 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
JP3283114B2 (ja) 1992-09-07 2002-05-20 クミアイ化学工業株式会社 縮合ヘテロ環誘導体及び農園芸用殺菌剤
JP2848232B2 (ja) 1993-02-19 1999-01-20 武田薬品工業株式会社 アルデヒド誘導体
RU2128186C1 (ru) 1993-04-28 1999-03-27 Кумиай Кемикал Индастри Ко., Лтд. Производные амидов аминокислот, способ получения, фунгицидная композиция для сельского хозяйства и садоводства
AU7375194A (en) * 1993-07-30 1995-02-28 Smithkline Beecham Corporation 3-cyano-3-(3,4-disubstituted)phenylcyclohexyl-1-carboxylates
AU691201B2 (en) 1993-11-01 1998-05-14 Japat Ltd. Endothelin receptor antagonists
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
IL112759A0 (en) * 1994-02-25 1995-05-26 Khepri Pharmaceuticals Inc Novel cysteine protease inhibitors
ATE195933T1 (de) 1994-03-10 2000-09-15 Searle & Co L-n6-(1-iminoethyl)lysin - derivate und ihre verwendung als no-synthase - inhibitoren
US5614649A (en) * 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
EP0821670A1 (en) * 1995-04-21 1998-02-04 Novartis AG N-aroylamino acid amides as endothelin inhibitors
WO1997027200A1 (en) 1996-01-26 1997-07-31 Smithkline Beecham Plc Thienoxazinone derivatives useful as antiviral agents
WO1998001133A1 (fr) 1996-07-08 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Inhibiteurs de la resorption osseuse
ID22499A (id) 1996-11-22 1999-10-21 Elan Pharmaceuticals Inc Cs Amida-amida asam n-(aril/heteroaril/alkilasetil) amino, komposisi farmasi yang terdiri dari amida asam amino tersebut, dan metode untuk menghambat pelepasan b-amiloid peptida dan/atau pembuatannya dengan menggunakan senyawa-senyawa tersebut
GB9723407D0 (en) * 1997-11-05 1998-01-07 Ciba Geigy Ag Organic compounds
JP4450988B2 (ja) 1997-11-05 2010-04-14 ノバルティス アーゲー ジペプチドニトリル
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
EP1155010A1 (en) 1999-02-20 2001-11-21 AstraZeneca AB Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s
JP2002537294A (ja) 1999-02-20 2002-11-05 アストラゼネカ アクチボラグ カテプシンｌ及びカテプシンｓの阻害剤としてのジ−及びトリペプチドニトリル誘導体
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
SK12882001A3 (sk) 1999-03-15 2002-04-04 Axys Pharmaceuticals, Inc. Zlúčeniny a prípravky ako proteinázové inhibítory
US6420364B1 (en) * 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
WO2001019808A1 (en) * 1999-09-16 2001-03-22 Axys Pharmaceuticals, Inc. Chemical compounds and compositions and their use as cathepsin s inhibitors
JP2001139320A (ja) * 1999-11-05 2001-05-22 Asahi Glass Co Ltd 球状シリカゲルの製造方法
ES2270898T3 (es) * 1999-12-24 2007-04-16 F. Hoffmann-La Roche Ag Derivados de nitrilo como inhibidores de catepsina k.
DE60132975T2 (de) * 2000-01-06 2009-02-26 Merck Frosst Canada Inc., Kirkland Neue substanzen und verbindungen als protease-inhibitoren
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PT1254124E (pt) 2008-11-03
EP1254124B1 (en) 2008-07-30
ZA200206218B (en) 2003-08-05
US6642239B2 (en) 2003-11-04
CN1636980A (zh) 2005-07-13
CN1183122C (zh) 2005-01-05
IL150406A0 (en) 2002-12-01
NO20023780L (no) 2002-08-09
CN1398260A (zh) 2003-02-19
KR20020072310A (ko) 2002-09-14
AU4642601A (en) 2001-08-20
CO5261578A1 (es) 2003-03-31
MY122826A (en) 2006-05-31
RU2002123350A (ru) 2004-01-10
CA2396158A1 (en) 2001-08-16
TWI258473B (en) 2006-07-21
HK1050197A1 (en) 2003-06-13
PE20020220A1 (es) 2002-03-25
GB0003111D0 (en) 2000-03-29
RU2005108133A (ru) 2006-09-10
NZ519940A (en) 2004-02-27
ATE402930T1 (de) 2008-08-15
JP3942895B2 (ja) 2007-07-11
PL357901A1 (en) 2004-07-26
ES2310177T3 (es) 2009-01-01
AR029466A1 (es) 2003-07-02
DE60135087D1 (de) 2008-09-11
MXPA02007768A (es) 2002-10-11
CA2396158C (en) 2010-02-02
HUP0300148A2 (en) 2003-05-28
US20030203919A1 (en) 2003-10-30
HUP0300148A3 (en) 2005-04-28
RU2265601C2 (ru) 2005-12-10
CZ20022721A3 (cs) 2002-11-13
US20010016207A1 (en) 2001-08-23
RU2293732C2 (ru) 2007-02-20
PL200119B1 (pl) 2008-12-31
AU764334B2 (en) 2003-08-14
SK11462002A3 (sk) 2003-01-09
BR0108118A (pt) 2003-02-25
US20070191392A1 (en) 2007-08-16
EP1254124A1 (en) 2002-11-06
US20050267129A1 (en) 2005-12-01
TR200201752T2 (tr) 2002-10-21
WO2001058886A1 (en) 2001-08-16
KR100544553B1 (ko) 2006-01-24
JP2003522764A (ja) 2003-07-29

Similar Documents

Publication Publication Date Title
NO20023780D0 (no) Dipeptid nitril katepsin K inhibitorer
CY2012007I2 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
NO20026283L (no) Inhibitorer av kobberholdige aminosydaser
NO20034045D0 (no) Metallproteinase-inhibitorer
EP1272467A4 (en) Cathepsin cysteine PROTEASE INHIBITORS
ATE524441T1 (de) Vla-4-inhibitoren
PT1370553E (pt) Inibidores de rhoquinase
DZ3318A1 (fr) Inhibiteur de proteinase
EE200300439A (et) Metalloproteinaasi inhibiitorid
NO20034032L (no) Metallproteinase-inhibitorer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20025786D0 (no) Protaseinhibitorer
NO20025005D0 (no) Proteaseinhibitorer
NO20032328D0 (no) Proteaseinhibitorer
AR028075A1 (es) Inhibidores de la peptido-desformilasa
DE60124397D1 (de) Inhibitoren von serinproteasen